REPLIGEN CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 149.1 USD | +0.61% |
|
-6.10% | -17.08% |
Presenter SpeechConor Noel McNamara (Analysts)Good morning, everyone, and welcome to the RBC C...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Companyâs chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Companyâs TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.
Calendar
2024-06-05
- William Blair Growth Stock Conference
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
148.2
USD
Average target price
204.2
USD
Spread / Average Target
+37.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.08% | 8.28B | |
| -7.16% | 177B | |
| -4.86% | 65.54B | |
| -4.28% | 47.09B | |
| +10.32% | 43.43B | |
| +8.14% | 41.77B | |
| +15.76% | 29.55B | |
| +15.53% | 24.83B | |
| -5.88% | 23.97B | |
| -5.38% | 23.54B |
- Stock Market
- Equities
- RGEN Stock
- News Repligen Corporation
- Transcript : Repligen Corporation Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 10
